MX355041B - Dominios de union a albumina consenso no naturales. - Google Patents

Dominios de union a albumina consenso no naturales.

Info

Publication number
MX355041B
MX355041B MX2014014384A MX2014014384A MX355041B MX 355041 B MX355041 B MX 355041B MX 2014014384 A MX2014014384 A MX 2014014384A MX 2014014384 A MX2014014384 A MX 2014014384A MX 355041 B MX355041 B MX 355041B
Authority
MX
Mexico
Prior art keywords
binding domains
albumin binding
natural consensus
consensus albumin
natural
Prior art date
Application number
MX2014014384A
Other languages
English (en)
Other versions
MX2014014384A (es
Inventor
Steven Jacobs
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2014014384A publication Critical patent/MX2014014384A/es
Publication of MX355041B publication Critical patent/MX355041B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a los dominios no naturales de unión a albúmina, polinucleótidos que codifican éstos y métodos para producir y usar estos dominios y polinucleótidos son útiles para controlar la vida media de moléculas terapéuticas para pacientes.
MX2014014384A 2012-05-25 2013-05-23 Dominios de union a albumina consenso no naturales. MX355041B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US201361776918P 2013-03-12 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Publications (2)

Publication Number Publication Date
MX2014014384A MX2014014384A (es) 2015-05-11
MX355041B true MX355041B (es) 2018-03-28

Family

ID=49622071

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014384A MX355041B (es) 2012-05-25 2013-05-23 Dominios de union a albumina consenso no naturales.

Country Status (16)

Country Link
US (3) US9156887B2 (es)
EP (1) EP2855509B1 (es)
JP (3) JP2015519345A (es)
KR (1) KR102053674B1 (es)
CN (1) CN104470944B (es)
AU (2) AU2013266215B2 (es)
BR (1) BR112014029409B1 (es)
CA (1) CA2874646C (es)
DK (1) DK2855509T3 (es)
EA (1) EA036487B1 (es)
ES (1) ES2670442T3 (es)
HK (1) HK1209134A1 (es)
IL (2) IL235808A (es)
MX (1) MX355041B (es)
PT (1) PT2855509T (es)
WO (1) WO2013177398A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
CA2902789A1 (en) * 2013-03-14 2014-09-18 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
CA2979973A1 (en) * 2015-04-29 2016-11-03 Mediolanum Farmaceutici S.P.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
US10456442B2 (en) * 2015-06-18 2019-10-29 Albert Einstein College Of Medicine FGF receptor ligands for treating diabetes and obesity
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
CN109153711B (zh) 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
WO2018111973A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd8a-binding fibronectin type iii domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10443049B2 (en) * 2017-01-24 2019-10-15 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)
CA3106549A1 (en) 2017-08-11 2019-02-14 The Board Of Trustees Of The University Of Illinois Truncated guinea pig l-asparaginase variants and methods of use
JP7545894B2 (ja) 2018-03-13 2024-09-05 アフィボディ アクティエボラーグ 新規足場に基づくポリペプチド
KR102282240B1 (ko) * 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
JP2023508885A (ja) * 2019-12-18 2023-03-06 アロ・バイオセラピューティクス・カンパニー 血清アルブミン結合性フィブロネクチンｉｉｉ型ドメインおよびその使用
US12037379B2 (en) 2021-04-14 2024-07-16 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
WO2024102190A2 (en) * 2022-11-09 2024-05-16 Avitide LLC Affinity agents
WO2024130179A1 (en) 2022-12-16 2024-06-20 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
EP0640135B1 (en) * 1992-05-07 2001-01-17 Affitech As Immunoglobulin binding proteins derived from l protein and their uses
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
DE69841578D1 (de) 1997-09-16 2010-05-06 Centocor Inc Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
AU2009267294B2 (en) 2008-06-30 2014-06-26 Kyowa Kirin Co., Ltd. Anti-CD27 antibody
SI2356269T1 (sl) * 2008-10-31 2016-10-28 Janssen Biotech, Inc. Ogrodni sestavki, postopki in uporabe na osnovi domene fibronektina tipa III
JP5557254B2 (ja) * 2009-02-10 2014-07-23 国立大学法人 琉球大学 薬物運搬体並びにこれを利用したアジュバントおよびワクチン
AU2010213892B2 (en) 2009-02-12 2014-10-23 Janssen Biotech, Inc. Fibronectin type III domain based scaffold compositions, methods and uses
ES2548030T3 (es) * 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
AU2011245225B2 (en) 2010-04-30 2015-09-17 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
US20130316952A1 (en) 2013-11-28
CN104470944A (zh) 2015-03-25
BR112014029409B1 (pt) 2022-11-29
US10280200B2 (en) 2019-05-07
AU2013266215A1 (en) 2014-12-04
US9156887B2 (en) 2015-10-13
EP2855509B1 (en) 2018-05-02
BR112014029409A2 (es) 2017-08-15
CA2874646A1 (en) 2013-11-28
CA2874646C (en) 2020-12-01
DK2855509T3 (en) 2018-07-23
EA036487B1 (ru) 2020-11-16
MX2014014384A (es) 2015-05-11
ES2670442T3 (es) 2018-05-30
WO2013177398A2 (en) 2013-11-28
US20160083436A1 (en) 2016-03-24
IL235808A (en) 2017-10-31
KR102053674B1 (ko) 2019-12-09
IL254652A0 (en) 2017-11-30
CN104470944B (zh) 2021-09-14
JP2021019595A (ja) 2021-02-18
AU2017261625A1 (en) 2017-12-07
WO2013177398A3 (en) 2014-03-27
JP7166081B2 (ja) 2022-11-07
PT2855509T (pt) 2018-08-03
IL254652B (en) 2019-12-31
IL235808A0 (en) 2015-01-29
AU2013266215B2 (en) 2017-12-07
JP2015519345A (ja) 2015-07-09
US20180009854A1 (en) 2018-01-11
KR20150016585A (ko) 2015-02-12
EA201590136A1 (ru) 2016-02-29
JP2018171063A (ja) 2018-11-08
EP2855509A4 (en) 2016-01-13
EP2855509A2 (en) 2015-04-08
AU2017261625B2 (en) 2019-11-21
HK1209134A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
AU2017261625B2 (en) Non-natural consensus albumin binding domains
PH12014501736B1 (en) Therapeutic use of p75ntr neurotrophin binding protein
DK3791896T5 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
MX2020010693A (es) Uso de peptidos glp-1 de accion prolongada.
NZ707086A (en) Anti-cd40 antibodies and methods of use
HK1245833B (zh) 用於治療、預防或緩解疼痛的融合蛋白和方法
AU2011328009A8 (en) Compounds and methods for treating pain
NZ709059A (en) Immunotherapy with binding agents
MX2015001083A (es) Polipeptidos de factor x modificados y usos de los mismos.
EP4276200A3 (en) Fgfr-tacc fusion proteins and methods thereof
MX341578B (es) Tratamiento de la osteoartritis y del dolor.
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
PH12014502406A1 (en) Anti-il-23p19 antibodies
MX2019003619A (es) Formulaciones de bromocriptina.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
NZ727446A (en) Therapeutic use of p75ntr neurotrophin binding protein
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
PL2943215T3 (pl) Peptydy pochodzące z laktoferycyny do zastosowania w leczeniu nowotworu
SA113340398B1 (ar) استخدام (s-(rs- سيكلوبروبيل-s-(4-{[4-{[(1r, 2r)-2- هيدروكسي-1- ميثيل بروبيل] أوكسي}-5-(تراي فلوروميثيل) بيريميدين-2- يل] أمينو} فنيل) سلفوكسيميد من أجل علاج أورام معينة
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.

Legal Events

Date Code Title Description
FG Grant or registration